Results 111 to 120 of about 19,142 (214)

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

GLP‐1 Receptor Agonists for the Prevention of New‐Onset Heart Failure: A Systematic Review and Meta‐Analysis of Placebo‐Controlled Randomized Clinical Trials

Obesity Reviews, Volume 27, Issue 4, April 2026.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) improve outcomes in heart failure (HF) with preserved ejection fraction. Whether GLP‐1 RA prevent new‐onset HF in Type 2 diabetes or obesity requires further investigation. Methods We performed an updated meta‐analysis of randomized placebo‐controlled trials (RCT) of treatment ...
João Sérgio Neves, Carolina B. Lobato, Ana Rita Leite, Catarina Vale, Francisco Vasques‐Nóvoa, Francisca Saraiva, Adelino Leite‐Moreira, Jens J. Holst, João Pedro Ferreira   +8 more
wiley   +1 more source

Correction to ‘Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population’

ESC Heart Failure, Volume 12, Issue 2, Page 1523-1523, April 2025.
wiley   +1 more source

Biventricular Impella Support for Ventricular Tachycardia Ablation in a Patient With Severe Dilated Cardiomyopathy

Clinical Case Reports, Volume 14, Issue 3, March 2026.
VT ablation with percutaneous biventricular Impella support in a patients with non‐ischemic dilated cardiomyopathy and severe biventricular failure. Segmented Inheart CT, angulation a.p. (a) and LAO (c). Segmentation revealed the prior ablation site (blue arrow) and extensive intramural fibrotic tissue (asterisk).
Madeleine Tydecks, Theresa Reiter, Gabriele Hessling, Isabel Deisenhofer, Mohammad Al Fayad   +4 more
wiley   +1 more source

Epicardial fat remodeling in end-stage heart failure with reduced ejection fraction. [PDF]

Cardiovasc Diabetol
Mączewski M, Załęska-Kocięcka M, Nowakowski M, Mazuruk M, Nogajski Ł, Czerwińska H, Gronek I, Smoliński M, Świstak A, Kurpias M, Łuniewska O, Kacperska M, Pilzak F, Wojdyńska Z, Michałowska I, Mączewski M, Paterek A, Leszek P.   +17 more
europepmc   +1 more source

From mechanistic promise to clinical translation: Passive heat therapy as a cardiovascular and functional adjunct in ageing and disease

Experimental Physiology, EarlyView.
Fergus K. O'Connor, Surendran Sabapathy, Aaron J. E. Bach, Bryce N. Balmain, Llion Roberts, Norman R. Morris   +5 more
wiley   +1 more source

Ninjurin1 in cardiovascular and vascular biology: From molecular mechanisms to therapeutic opportunities

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
NINJ1 mediates PMR in cardiovascular cell death, releasing DAMPs that amplify vascular inflammation. Dual NINJ1 paradox: membrane‐bound form drives endothelial NF‐κB/CXCL‐8 inflammation while soluble form provides atheroprotection. Pericyte NINJ1 regulates the critical balance between angiogenic sprouting and vessel maturation in ischaemic tissues ...
Muhammad Mamunur Rashid Mahib
wiley   +1 more source

Trends in Healthcare Costs in Heart Failure and Its Clinical Phenotypes During the Implementation of SGLT2 Inhibitors: A Finnish Registry Study. [PDF]

Clinicoecon Outcomes Res
Hansen JL, Tarkia M, Vasilevska M, Sandin P, Asllanaj E, Wammes K, Mesterton J, Airaksinen KEJ.   +7 more
europepmc   +1 more source

MRA use in patients with HFrEF [PDF]

Nature Reviews Cardiology, 2012
openaire   +2 more sources

LKB1–AMPK Signaling Pathway in Cardiovascular and Other Diseases

MedComm, Volume 7, Issue 3, March 2026.
The LKB1–AMPK pathway has a central regulatory role in various diseases. Dysfunction of this pathway can lead to pathological processes in cardiovascular diseases (atrial fibrillation, myocardial infarction, myocardial hypertrophy, atherosclerosis), metabolic diseases (diabetes and kidney disease), neurodegenerative diseases (Alzheimer's disease ...
Zhuo Chen, Qin Yang, Guo‐Wei He
wiley   +1 more source